Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Scott N Gettinger

6PUBLICATIONS

109CO-AUTHORS

Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Jul 10, 2024

Phase II Trial of Afatinib in Patients With <i>EGFR</i>-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.

Scott N Gettinger, Zihe Song, Karen L Reckamp

|Apr 02, 2024

Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.

Adam J Schoenfeld, Sylvia M Lee, Bernard Doger de Spéville

|Feb 15, 2024

ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.

Bomiao Hu, Marc Wiesehöfer, Fernando J de Miguel

|Jan 26, 2024

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.

Edwin Roger Parra, Jiexin Zhang, Dzifa Yawa Duose

|Apr 21, 2023

Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).

Shing M Lee, Weijia Fan, Aijin Wang

|Jan 15, 2021

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

Hossein Borghaei, Scott Gettinger, Everett E Vokes

Pageof 1

Frequent Collaborators

2 joint publications

Lyudmila Bazhenova

2 joint publications

Roy S Herbst

2 joint publications

Mary W Redman

1 joint publications

Keith T Flaherty

1 joint publications

Everett E Vokes

1 joint publications

Laura Q M Chow

1 joint publications

Javier de Castro Carpeno

1 joint publications

Oscar Arrieta

1 joint publications

Bruno Coudert

1 joint publications

David Waterhouse

Frequent Collaborators

2 joint publications

Lyudmila Bazhenova

2 joint publications

Roy S Herbst

2 joint publications

Mary W Redman

1 joint publications

Keith T Flaherty

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on : Aug 14, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on : Nov 22, 2021

See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on : Aug 14, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on : Nov 22, 2021

See more related videos